NASDAQ$SANA
Sana Biotechnology Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Sana Biotechnology reported financial results for the first quarter of 2024 and provided business updates.
Sana Biotechnology reported a net loss of $107.5 million for Q1 2024. The company completed a financing round of $189.8 million and has a cash position of $311.1 million. They are advancing four clinical programs and expect to share initial data from these studies in 2024.
- Advancing four clinical programs across seven indications.
- Completed financing of $189.8 million in gross proceeds.
- Cash position of $311.1 million as of March 31, 2024.
- Expect initial clinical data in 1H2024 for investigator-sponsored trial with hypoimmune-modified primary islet cells.
Headline financials
Revenue & EPS history
Sana · Revenue · Quarterly
$0
Forward guidance
Sana Biotechnology aims to treat 40-60 patients in 2024 across four trials and seven indications, with multiple data readouts expected.
Tailwinds
- Goal to treat 40-60 patients in 2024 in four trials across seven indications.
- Expect to report additional data in 2024 from the ARDENT trial for SC291 in B-cell malignancies.
- Expect to report initial clinical data in 2024 from the GLEAM trial for SC291 in B-cell mediated autoimmune diseases.
- Expect to report initial clinical data in 2024 from the VIVID trial for SC262 in relapsed/refractory B-cell malignancies.
- Expect initial clinical data in 1H2024 for investigator-sponsored trial with hypoimmune-modified primary islet cells.
Headwinds
- Risks inherent in drug development, including initiation, cost, timing, progress, and results of research and development programs.
- Economic, market, and social disruptions could affect actual results.
- Uncertainties related to preclinical and clinical trials.
- Reliance on current expectations, estimates, forecasts and projections about future events and financial trends.
- Potential variability in actual results due to inherent uncertainties in forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-1.2%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+4.1%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+22.3%
Q2 2022
Best reaction
-25.3%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.5% | -15.3% | -18.6% | |
| Q3 2025 | -0.2% | +3.9% | +25.7% | |
| Q2 2025 | +7.3% | +14.0% | +16.4% | |
| Q1 2025 | +0.6% | -1.7% | +56.9% | |
| Q4 2024 | -17.7% | -16.6% | -40.4% | |
| Q3 2024 | -6.8% | -14.2% | -25.8% | |
| Q1 2024 | -25.3% | -21.2% | -30.5% | |
| Q4 2023 | +5.6% | -8.1% | -6.3% | |
| Q3 2023 | -14.8% | -10.3% | -4.1% | |
| Q2 2023 | -3.8% | -1.3% | -4.5% | |
| Q1 2023 | +7.2% | +11.8% | +8.9% | |
| Q4 2022 | +2.3% | +2.3% | +51.8% | |
| Q3 2022 | -14.1% | -21.6% | -22.2% | |
| Q2 2022 | +22.3% | +18.3% | -3.0% | |
| Q1 2022 | -5.6% | -11.9% | -11.4% | |
| Q4 2021 | +21.1% | +19.5% | +45.6% | |
| Q3 2021 | -5.7% | -3.3% | -19.2% | |
| Q2 2020 | +10.2% | +9.5% | +40.5% | |
| Q2 2021 | +10.2% | +9.5% | +40.5% | |
| Q1 2021 | -13.1% | -1.9% | +9.9% | |
| Q4 2020 | -5.7% | -4.1% | -23.7% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro